Endologix (ELGX) Hits New 52-Week Low at $0.86
Endologix, Inc. (NASDAQ:ELGX) hit a new 52-week low during trading on Tuesday . The stock traded as low as $0.86 and last traded at $0.88, with a volume of 15261 shares changing hands. The stock had previously closed at $0.94.
Several brokerages have commented on ELGX. Zacks Investment Research raised shares of Endologix from a “sell” rating to a “hold” rating and set a $1.50 target price for the company in a research note on Friday, November 2nd. BidaskClub downgraded shares of Endologix from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 25th. Oppenheimer set a $3.00 target price on shares of Endologix and gave the company a “hold” rating in a research note on Friday, November 2nd. BTIG Research reaffirmed a “buy” rating on shares of Endologix in a research note on Sunday, November 4th. Finally, Piper Jaffray Companies downgraded shares of Endologix from an “overweight” rating to a “neutral” rating in a research note on Friday, August 10th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $3.08.
The company has a current ratio of 1.55, a quick ratio of 0.96 and a debt-to-equity ratio of 4.38. The company has a market cap of $105.52 million, a P/E ratio of -1.77 and a beta of 0.43.
Hedge funds have recently modified their holdings of the company. Jane Street Group LLC bought a new stake in shares of Endologix during the third quarter worth $116,000. Renaissance Technologies LLC bought a new stake in shares of Endologix during the third quarter worth $165,000. Paloma Partners Management Co bought a new stake in shares of Endologix during the third quarter worth $184,000. MetLife Investment Advisors LLC increased its position in shares of Endologix by 128.2% during the second quarter. MetLife Investment Advisors LLC now owns 41,313 shares of the medical instruments supplier’s stock worth $234,000 after acquiring an additional 23,210 shares in the last quarter. Finally, Engineers Gate Manager LP increased its position in shares of Endologix by 66.5% during the third quarter. Engineers Gate Manager LP now owns 129,959 shares of the medical instruments supplier’s stock worth $248,000 after acquiring an additional 51,886 shares in the last quarter. 75.51% of the stock is owned by institutional investors.
About Endologix (NASDAQ:ELGX)
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.
Further Reading: Coverage Ratio
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.